Clients in the media Clients IN the MEDIA

Ensuring your story is visible.

OncoCyte Launches NSCLC Stratification Test, Looks beyond Lung Cancer

OncoCyte president and CEO Ron (Ronnie) Andrews discussed the company’s recent acquisitions and expansion of its diagnostics menu with GEN Edge . . .

Soon-Shiong’s Nantkwest, Immunitybio still chasing cancer breakthroughs

Pharma Technology Focus: treating zebras

Horizon 2020, the European Union’s research and innovation programme, is entering its final year. But how has the money been used to drive pharma developments in the region? We round up the most successful and innovative projects to emerge from scheme.

HPV-Cancer Targeting Immunotherapy Enters Phase 1 Clinical Trial After Showing Success In Animals

This week the publishing of data on Cue Biopharma’s star immunotherapy molecule, Cue 101, revealed just how much reality there is to concept. A paper published in Clinical Cancer Research on Tuesday showed research demonstrating the ability of a biologic immunotherapy drug candidate named CUE-101 to activate tumor antigen-specific antitumor immunity.

Krystal Biotech Names Genzyme’s Chien Chief Commercial Officer

Gene therapy developer Krystal Biotech (NASDAQ: KRYS) has appointed Jennifer Chien to the newly created role of chief commercial officer. She comes to Pittsburgh-based Krystal from the Genzyme unit of Sanofi (NYSE: SNY), where she was vice president and head of genetic diseases.

Orasis Developing Eye Drops as Alternative to Reading Glasses

As people age, the ability of their eyes to focus on objects near to them weakens. The condition, known as presbyopia, affects more than 1.8 billion people worldwide. Though reading glasses provide a solution to the problem, Orasis Pharmaceuticals is developing a corrective eyedrop it says will provide an alternative.

Immuneering Raises $20 Million for New Drug-Discovery Effort

Venture capitalists are betting $20 million that technology from Immuneering Corp. will enable it to develop medicines aimed at molecular targets that have long tantalized and eluded drugmakers.

2020 Could be a Defining Year for SQZ Biotech

If 2019 was a breakthrough year for Watertown, Mass.-based SQZ Biotech, 2020 could be a defining year as the company tests is first antigen-presenting cell asset in the clinic to treat solid tumors that are HPV positive.